Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bioventus Inc. (BVS : NSDQ)

• Company Description    Bioventus Inc. delivers clinically proven, cost-effective products which help people heal quickly and safely. It includes offerings for osteoarthritis, surgical and non-surgical bone healing. Bioventus Inc. is based in DURHAM, N.C. Number of Employees: 930

• Price / Volume Information    Yesterday's Closing Price: $14.07 Daily Weekly Monthly 20 Day Moving Average: 549,150 shares Shares Outstanding: 84.09 (millions) Market Capitalization: $1,183.17 (millions) Beta: 0.65 52 Week High: $15.89 52 Week Low: $6.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.79% 1.24% 12 Week 63.60% 60.12% Year To Date 89.11% 67.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4721 EMPEROR BOULEVARD SUITE 100 - DURHAM,NC 27703 USA ph: 919-474-6700 fax: - investor.relations@bioventus.com http://www.bioventus.com

• General Corporate Information    Officers Robert E. Claypoole - President; Chief Executive Officer and Director William A. Hawkins III - Chairman Mark L. Singleton - Senior Vice President and Chief Financial Officer Ajay Dhankhar - Director Mary Kay Ladone - Director Peer Information Bioventus Inc. (GSAC) Bioventus Inc. (CASIF) Bioventus Inc. (ALCD.) Bioventus Inc. (OMNN) Bioventus Inc. (CGPI.) Bioventus Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 09075A108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 84.09 Most Recent Split Date: (:1) Beta: 0.65 Market Capitalization: $1,183.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.79 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 10.00% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: 17.92 Trailing 12 Months: 18.51 PEG Ratio: 1.79 Price Ratios Price/Book: 4.26 Price/Cash Flow: 11.03 Price / Sales: 2.03 EPS Growth vs. Year Ago Period: 4.76% vs. Previous Quarter: 46.67% Sales Growth vs. Year Ago Period: 3.76% vs. Previous Quarter: 15.99% ROE 06/30/26 - 28.08 03/31/26 - 29.97 12/31/25 - 28.88 ROA 06/30/26 - 9.82 03/31/26 - 9.52 12/31/25 - 8.53 Current Ratio 06/30/26 - 1.69 03/31/26 - 1.69 12/31/25 - 1.70 Quick Ratio 06/30/26 - 1.17 03/31/26 - 1.13 12/31/25 - 1.19 Operating Margin 06/30/26 - 11.43 03/31/26 - 11.33 12/31/25 - 10.45 Net Margin 06/30/26 - 9.36 03/31/26 - 4.94 12/31/25 - 4.00 Pre-Tax Margin 06/30/26 - 6.64 03/31/26 - 5.84 12/31/25 - 4.53 Book Value 06/30/26 - 3.30 03/31/26 - 2.80 12/31/25 - 2.76 Inventory Turnover 06/30/26 - 2.14 03/31/26 - 2.02 12/31/25 - 1.95 Debt-to-Equity 06/30/26 - 0.83 03/31/26 - 1.08 12/31/25 - 1.22 Debt-to-Capital 06/30/26 - 45.30 03/31/26 - 51.96 12/31/25 - 54.98

Powered by Zacks Investment Research ©